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13 Abstract
14 Host environment is a crucial factor for considering the transplant of stem cell-derived immature 
15 pancreatic cells in patients with type 1 diabetes. Here, we investigated the effect of insulin-deficient 
16 diabetes on the fate of immature pancreatic endocrine cell grafts and the underlying mechanisms. 
17 Human induced pluripotent stem cell-derived pancreatic endocrine progenitor cells (EPCs), which 
18 contained a high proportion of chromogranin A+ NK6 homeobox 1+ cells while very few insulin+ cells, 
19 were used. When the EPCs were implanted under the kidney capsule in immunodeficient mice, insulin-
20 deficient diabetes accelerated increase in plasma human C-peptide, a marker of graft-derived insulin 
21 secretion. The acceleration was suppressed by insulin infusion but not affected by partial attenuation 
22 of hyperglycemia by dapagliflozin, an insulin-independent glucose-lowering agent. 
23 Immunohistochemical analyses indicated that the grafts from diabetic mice contained more endocrine 
24 cells including proliferative insulin-producing cells compared to that from non-diabetic mice, despite 
25 no difference in whole graft mass between the two groups. These data suggest that insulin-deficient 
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1 diabetes upregulates the insulin secreting capacity of EPC grafts by increasing number of endocrine 
2 cells including insulin producing cells without changing graft mass. These findings would provide 
3 useful insights into postoperative diabetic care for cell therapy using stem cell-derived pancreatic cells.
4
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1 Introduction
2 Type 1 diabetes mellitus (T1DM), caused by the insufficient insulin production due to the 
3 autoimmune destruction of pancreatic -cells, includes a small subset with uncontrollable glycemia 
4 despite current insulin therapy, called by brittle T1DM (1). In these patients, the quality of life is 
5 dramatically threatened by impaired awareness of hypoglycemia and severe hypoglycemic events. 
6 Pancreatic islet transplantation is reported to be effective for these patients (2). However, donor 
7 shortage is a major obstacle for the promising therapeutic option. In recent years, alternative cell 
8 sources such as islets derived from human stem cells and xenogeneic animals have been intensively 
9 investigated to overcome donor shortage (3, 4).
10 Many studies have shown that the generation of pancreatic endocrine cells from human 
11 embryonic stem cells (hESCs)/human induced pluripotent stem cells (hiPSCs) has the potential to cure 
12 T1DM in small animal models (5-7). Most of the studies utilized in vitro stepwise differentiation 
13 protocols based on the knowledge from the developmental processes of pancreas, islets, and β-cells 
14 (8). Despite rapid progress, generating fully functional endocrine cell clusters which replicate all 
15 aspects of adult islet cells has remained elusive (9). This implies the significance of in vivo 
16 differentiation/maturation process post implantation.
17 Implanted cells are generally exposed to the multiple environmental factors in the host like　
18 humoral factors and cell-to-cell interaction with other cells. These factors affect engraftability, cell 
19 cycle, and function. Besides, for immature cells, these affect their differentiation/maturation process. 
20 In fact, host sex (10) and hypothyroidism (11) have shown to affect the differentiation/maturation 
21 process of implanted immature pancreatic cells generated in vitro. Although clinical trials with use of 
22 hESC-derived immature pancreatic cells for T1DM have been conducted (12, 13), the effect of diabetes 
23 in the recipients on the fate of implanted cells has not been elucidated.
24 Streptozotocin (STZ)-induced diabetic condition has been reported to enhance increase in plasma 
25 levels of human C-peptide, a marker of insulin secretion, after implantation of hESC-derived 
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1 pancreatic endoderm cells (PECs) in immunodeficient mice (14). After implantation, a part of 
2 engrafted PECs is considered to differentiate into endocrine progenitor cells (EPCs), immature 
3 hormone-positive cells, and then maturate into adult-type endocrine cells including β-cells or islets 
4 that secrete insulin/C-peptide into the circulation. The study has attributed the increase in plasma hC-
5 peptide levels to acceleration of differentiation of implanted PECs (14). However, it encompasses 
6 diverse aspects of cell fate such as engraftability, differentiation/maturation process, and proliferation 
7 ability. Additionally, STZ-induced diabetic condition is composed of hypo-insulinemia and 
8 hyperglycemia followed by metabolic changes in the whole body. The involvement of multiple factors 
9 necessitates the investigation of the detailed mechanism behind the phenomenon.
10 EPCs are the early-stage endocrine cell type that proceed to development toward hormone-
11 positive cells from PECs. Therefore, compared to PECs, EPCs can be more useful to understand the 
12 fate of immature endocrine cells under a host environment because the influence of differentiation 
13 process into EPCs can be disregarded. Additionally, since EPCs theoretically contain less progenitors 
14 with potential to differentiate into non-endocrine cells than PECs, EPCs may be preferable for 
15 transplantation. The purpose of this study is to investigate the effect of insulin-deficient diabetes on 
16 the fate of immature endocrine cell grafts and the underlying mechanisms using EPCs generated in 
17 vitro from hiPSCs. We demonstrated, for the first time to our knowledge, that insulin-deficient diabetic 
18 condition upregulates the insulin secreting capacity of EPC grafts in immunodeficient mice. We further 
19 showed that the diabetic condition positively affected EPC grafts resulting in an increase in number of 
20 endocrine cells including insulin producing cells without changing the graft mass.
21
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1 Research Design and Methods
2 In vitro differentiation of hiPSCs
3 Two hiPSC lines for non-clinical use (Ff-I14s14 and Ff-WJ18) were provided by the Center for 
4 iPS Cell Research and Application of Kyoto University (Kyoto, Japan) and maintained and passaged 
5 in StemFit AK03N medium (Ajinomoto, Tokyo, Japan). The cells were directed into key stages of 
6 pancreatic development, including definitive endoderm (Stage 1), primitive gut tube (Stage 2), 
7 posterior foregut (Stage 3), pancreatic endoderm (Stage 4), and endocrine progenitor (Stage 5) in vitro 
8 taking total 16 or 17 days. The differentiation protocols were based on those previously reported with 
9 some modifications [Stages 1-4 (5, 15-17), Stages 3-5 (18), and Stage 5 (19, 20)]. The detail is provided 
10 as follows, and the brief schematic diagram is shown in Figure 1A. The use of hiPSCs was approved 
11 by ethical review committee of Takeda Pharmaceutical Company Limited and Kyoto University.
12 Stage 1: Undifferentiated hiPSCs were resuspended with Stage 1 medium containing Roswell 
13 Park Memorial Institute (RPMI) 1640 medium (12633012; Thermo Fisher Scientific, Waltham, MA, 
14 USA) supplemented with 2% (v/v) B27 (17504001; Thermo Fisher Scientific), 1% (v/v) 
15 penicillin/streptomycin (P/S; 168-23191; FUJIFILM Wako, Osaka, Japan), 5-100 ng/ml activin A 
16 (R&D Systems, Minneapolis, MN, USA), 3 μM CHIR99021 (Axon Medchem, Groningen, 
17 Netherlands), 10 μM Y-27632 (FUJIFILM Wako), and 1% (v/v) DMSO (045-24511; FUJIFILM 
18 Wako), seeded on iMatrix-511 (381–07363; Wako)-coated plates at a density of 1-2 × 105 cells/cm2, 
19 and cultured for 1 day. For the next 2 days, the cells were cultured in RPMI 1640 medium with 2% 
20 B27, 1% P/S, 5-100 ng/ml activin A, and 1% DMSO. When using activin A at 100 ng/ml, 1% DMSO 
21 was not used to supplement in the medium.
22 Stage 2: Cells were exposed to Improved MEM Zinc Option (iMEM) medium (Thermo Fisher 
23 Scientific) supplemented with 1% B27, 1% P/S (iMEM-B27), and 50 ng/ml keratinocyte growth factor 
24 (KGF; R&D Systems) for 4 days.
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1 Stage 3: Culturing was continued for 2 or 3 days in iMEM-B27 with 50 ng/ml KGF, 0.5 μM 3-
2 keto-N-aminoethyl-N'-aminocaproyldihydrocinnamoyl cyclopamine (KAAD-CYC; Toronto 
3 Research Chemicals, Toronto, Canada), 10 nM 4-[(E)-2-(5,6,7,8-tetrahydro- 5,5,8,8-tetramethyl-2-
4 naphthalenyl)-1-propenyl] benzoic acid (TTNPB; Santa Cruz Biotechnology, Dallas, TX, USA), 100 
5 ng/ml NOGGIN (Pepro-tech, Rocky Hill, NJ, USA), and 250 μM L-ascorbic acid (A4544; Sigma-
6 Aldrich, St. Louis, MO, USA).
7 Stage 4: Cells were dissociated into single cells by gentle pipetting after treatment with 0.25% 
8 trypsin–EDTA and seeded on iMatrix-511-coated plates at a density of 3-4 × 105 cells/cm2. Then, the 
9 cells were cultured for 4 days in iMEM-B27 with 100 ng/ml KGF, 50 ng/ml epidermal growth factor 
10 (EGF; R&D Systems), 10 mM nicotinamide (VERITAS, Tokyo, Japan), 50 μM Y-27632, and 250 μM 
11 L-ascorbic acid.
12 Stage 5: For aggregation cultures, cells were dissociated into single cells as described above, and 
13 seeded on a low-binding 96-well plate at a density of 30 × 103 cells/well. Then, the cells were cultured 
14 for 3 or 4 days in iMEM-B27 with 250 nM SANT-1 (S4572; Sigma-Aldrich), 50 nM retinoic acid 
15 (Sigma-Aldrich), 10 μM ALK5 inhibitor II (SC-221234A; Santa Cruz Biotechnology), 100 nM 
16 LDN193189 hydrochloride (HY-12071A; Medchemexpress, Monmouth Junction, NJ, USA), 1 μM L-
17 3,3ʹ,5-triiodothyronine (64245; Merck Millipore, Burlington, MA, USA), 1 μM XAV939 (X3004; 
18 Sigma-Aldrich), 50 ng/ml basic fibroblast growth factor (100-18B; Pepro Tech, London, UK), 1 μM 
19 -secretase inhibitor XXI (Compound E, 565790; Merck Millipore), and 10 μM Y-27632. The 
20 resulting aggregates were used for implantation studies.
21 Additional information on EPCs used in this study is provided in Supplementary Table 1. The 
22 differentiation quality at each stage, based on the developmental processes of pancreatic endocrine 
23 cells, was assessed by flow cytometry and immunostaining as described previously (5). The antibodies 
24 used are detailed in Supplementary Table 2. Differentiation of EPCs into insulin-producing cells in 
Page 7 of 46
For Peer Review Only
Diabetes




5 Male 7 to 15-week-old NOD.CB17-Prkdcscid/J mice (NOD/SCID; Charles River Laboratories 
6 Japan, Kanagawa, Japan) were rendered as diabetic models by daily intraperitoneal injection with 50 
7 mg/kg of STZ (Sigma-Aldrich) for 5 consecutive days. Age-matched male NOD/SCID mice were 
8 similarly injected with 0.05 M citrate buffer (pH 4.5) and used as non-diabetic models. Diabetic Akita-
9 NOD/SCID mice were generated by crossing of male AKITA/Slc mice (Akita; Japan SLC, Shizuoka, 
10 Japan) and female NOD/SCID mice. Mice showing hyperglycemia were selected from the offspring 
11 mice and backcrossed for >10 generations with NOD/SCID mice. Both SCID and Ins2Akita mutation 
12 were confirmed by PCR-based genotyping. Age-matched NOD/SCID mice without Ins2Akita mutation 
13 were used as wild type (WT) non-diabetic models. Animals had ad libitum access to normal diet (CE-2; 
14 CLEA Japan, Inc., Tokyo, Japan) and tap water unless otherwise stated, and were housed individually 
15 under controlled temperature (20-26°C), humidity (40-70%), and a 12 h light/12 h dark cycle. All 
16 animal experiments were conducted based on protocols reviewed by the Institutional Animal Care and 
17 Use Committee of Takeda Pharmaceutical Co., Ltd. For all implantation studies, mice were divided 
18 into groups based on data of non-fasting blood glucose level and body weight.
19
20 Implantation and in vivo assessment of grafts
21 Mice were anesthetized with inhalable isoflurane, and then 192 hiPSC-derived EPC cell 
22 aggregates (30 × 103 cells/aggregate) were implanted under the left kidney capsule. EPCs from the 
23 same batches were divided between implant recipients in individual studies. Sham-operated mice were 
24 also prepared in some experiments. All mice received a single subcutaneous injection of meloxicam 
25 (1 mg/kg, Metacam; Boehringer-Ingelheim, Ingelheim am Rhein, Germany) at the time of implantation. 
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1 At the indicated weeks post-implantation, blood samples were collected from the tail vein without 
2 anesthesia and placed in chilled tubes containing heparin and aprotinin, and centrifuged at 4°C to 
3 isolate the plasma. Plasma levels of hC-peptide were measured to assess the insulin secreting capacity 
4 and function of grafts. In oral glucose tolerance test, glucose was administered orally (2 g/kg) in 
5 overnight fasted mice. After the glucose loading, blood samples were collected at the indicated times.
6
7 Insulin infusion
8 STZ-induced diabetic NOD/SCID mice were subcutaneously administered human insulin (50 
9 nmol/kg/day; Peptide Institute, Osaka, Japan) by infusion from an implanted osmotic pump (Model 
10 1002, Alzet; DURECT Corporation, Cupertino, CA, USA) for 14 days, and only mice showing blood 
11 glucose lowering by the treatment received EPC implants. At the time of EPC implantation and at 4 
12 weeks and 8 weeks after the implantation, the osmotic pump was replaced with a new pump (Model 
13 1004, Alzet; DURECT Corporation) to sustain insulin infusion up to 11 weeks after the implantation. 
14 To prevent hypoglycemic condition, insulin dosage was individually adjusted to 40-60 nmol/kg/day 
15 based on non-fasting blood glucose levels. Age-matched STZ-induced diabetic NOD/SCID mice 
16 without exogenous insulin infusion and non-diabetic NOD/SCID mice also received EPC implants.
17
18 High-fat diet (HFD) feeding
19 Non-diabetic 7-week-old NOD/SCID mice were implanted with EPCs, and thereafter fed with a 
20 HFD (60% calories from fat; D12492; Research Diets, Inc., New Brunswick, NJ, USA) up to 12-week 
21 after the implantation. Age-matched non-diabetic NOD/SCID mice fed CE-2 (4.5% calories from fat) 
22 were used as control diet (CD) group.
23
24 Repeated dosing of dapagliflozin
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1 STZ-induced diabetic NOD/SCID mice were orally administered vehicle (0.5% methylcellulose, 
2 w/v) or a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (10 mg/kg, 
3 suspended in the vehicle solution) once daily for 4 weeks. Each of the treatment groups was divided 
4 into two groups and received EPC implant or the sham operation. After that, the treatment of vehicle 
5 or dapagliflozin was continued for 12 weeks. Age-matched non-diabetic NOD/SCID mice with similar 
6 vehicle treatment were also prepared and received EPC implants. Dapagliflozin was purchased from 
7 Nard Institute, Ltd., Japan.
8
9 Immunofluorescence staining
10 The cell aggregates used for implantation and engrafted kidneys harvested at 6 weeks post-
11 implant were fixed with 4% paraformaldehyde for 1 to 2 days at 4°C and processed for immunostaining 
12 as described previously (5). The antibodies used are provided in Supplementary Table 2. Fluorescence 
13 imaging was performed using BZ-X710 fluorescence microscope (Keyence, Osaka, Japan). Areas of 
14 the whole graft and chromogranin A (CHGA), NK6 homeobox 1 (NKX6.1), insulin (INS), and 
15 glucagon (GCG)-immunoreactive cells were analyzed using cellSens Dimension software (Olympus, 
16 Tokyo, Japan). Quantification of immunoreactive area was performed by the same method reported 
17 by Bruin et al. (21); immunofluorescence staining was performed on three to four sections per graft 
18 sample, separated at least by 100 µm, and the average of all sections was used to represent each graft. 
19 Total graft area per section was set based on the border of renal parenchyma. Counting of INS+Ki67+ 
20 cells was manually performed under blind condition using three to four sections per graft sample, 
21 separated at least by 100 µm, and the average of all sections was used to represent each graft.
22
23 Measurement of blood and plasma parameters
24 Blood glucose was measured by ACCU-CHEK Aviva (Roche Diagnostics K.K, Tokyo, Japan). 
25 Plasma levels of human C-peptide and human insulin were measured by respective enzyme-linked 
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1 immunosorbent assay (ELISA) kits (Mercodia, Uppsala, Sweden). Plasma mouse insulin was also 
2 measured with Morinaga mouse insulin ELISA kit (Morinaga Institute of Biological Science, Inc., 
3 Kanagawa, Japan).
4
5 Measurement of hormone contents
6 Whole grafts carefully peeled off the recipient’s kidneys were measured for the weights and 
7 contents of human insulin and glucagon as follows. The whole graft samples were homogenized in an 
8 ethanol/HCl solution and then incubated overnight at 4°C. After removing the debris by centrifugation, 
9 concentrations of human insulin and glucagon were measured with respective ELISA kits (Mercodia). 
10 Similar preparations were performed on cell aggregates to measure hormone contents. Insulin content 
11 in the pancreas was measured similarly using a piece of the tissue, and with mouse insulin ELISA kit 
12 (Morinaga Institute of Biological Science, Inc.).
13
14 Statistics
15 Data were expressed as mean and standard deviation (SD) values. Statistical difference between 
16 two animal groups was analyzed with Student’s or Aspin-Welch’s t-test, and adjustment for multiple 
17 testing was performed using the Bonferroni method. Analysis of variance (ANOVA) was used to 
18 evaluate the difference in levels of blood and plasma parameters among animal groups. Alternatively, 
19 statistical significance was first analyzed using Bartlett’s test for homogeneity of variances, followed 
20 by Bonferroni-adjusted Dunnett’s test for multiple comparisons.
21
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1 Results
2 In vitro generated EPCs largely contain the early-stage pancreatic endocrine cells.
3 We differentiated hiPSC line Ff-I14s04 toward EPCs by protocols shown in Figure 1A. After 
4 efficient differentiation of stage 1 [SRY-box (SOX)17+forkhead box (FOX)A2+] and stage 4 
5 [pancreatic and duodenal homeobox 1(PDX1)+NKX6.1+] (Supplementary Fig. 2A and 2B) as 
6 previously reported (5), cells were dissociated and aggregated for endocrine cell commitment at stage 
7 5. We sequentially obtained definitive endoderm (SOX17+), pancreatic endoderm (PDX1+NKX6.1+), 
8 and endocrine/endocrine precursor (CHGA+) (22) cells at the average induction rate of 98.6±1.1%, 
9 90.1±0.6%, and 59.4±4.2%, respectively. The majority (52.9±4.0%) of the CHGA+ cells expressed 
10 NKX6.1, indicating the potential to be β-cells. On the other hand, the cells comprised very few INS- 
11 and GCG-expressing cells (Fig. 1B and 1C). Representative flow cytometry plots analyzing each stage 
12 marker regarding one sequential inducting experiment are shown in Supplementary Figure 1 and 
13 Figure 1D. We did not detect an immunofluorescence signal of an endocrine progenitor marker 
14 neurogenin-3 (NGN3) in the large population of EPCs we generated (Supplementary Fig. 2C), as its 
15 expression pattern was transient during stage 5 (Supplementary Fig. 3) in agreement with a previous 
16 report (23). We thereby describe the cell population in which the timing of expression peak of NGN3 
17 passes as EPCs. The EPC aggregates used for implantation studies contained a part of fetal pancreatic 
18 epithelial marker cytokeratin 19 (CK19) (24)-expressing cells and few exocrine marker Trypsinogen- 
19 and multipotential progenitor marker SOX9 (25)-expressing cells (Supplementary Fig. 2C).
20
21 Implanted EPCs secrete more insulin in insulin-deficient diabetic host than in non-diabetic host.
22 To investigate whether insulin-deficient diabetic condition in host regulates the fate of implanted 
23 EPCs, we implanted them under the kidney capsule of STZ-induced diabetic NOD/SCID mice and 
24 evaluated the graft function. In STZ treated-diabetic mice non-fasting blood glucose maintained high 
25 levels (average: 504-576 mg/dl) compared with the mice without STZ-treatment. But, the EPC 
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1 implantation decreased blood glucose levels after 12 weeks and normalized (average 82-93 mg/dl) 
2 after 18 weeks (Fig. 2A). Plasma human C-peptide, an indicator of insulin derived from the grafts, 
3 increased with time in both EPCs implanted groups but was higher in STZ-treated mice (STZ+EPCs) 
4 than mice without STZ-treatment (non-STZ+EPCs) during the early post-implantation period (4 to 13 
5 weeks) (Fig. 2B). The levels were on a plateau after reaching about 700 pM in both groups. Notably, 
6 blood glucose was normal range during plateau period of plasma human C-peptide in STZ+EPCs. 
7 Endogenous insulin deficiency in diabetic mice was not affected by the EPC implantation and dramatic 
8 decrease in plasma levels of mouse C-peptide during the early post-implantation period was confirmed 
9 in STZ+EPCs compared to non-STZ+EPCs (Supplementary Fig. 4). These results suggest that the 
10 diabetic environment upregulates insulin secreting capacity of the EPC grafts. 
11 To examine whether the diabetic condition promotes maturation of insulin-producing/secreting 
12 cells in grafts as β-cells, we compared plasma human C-peptide levels in fasting and non-fasting states 
13 on 13 and 18 weeks post-implantation. Plasma levels of human C-peptide decreased in response to an 
14 overnight fast in both STZ+EPCs and non-STZ+EPCs (Fig. 2C and 2D). Additionally, trends and 
15 levels of human C-peptide secretion were identical in both groups when mice were orally administered 
16 glucose, suggesting that β-cell maturation in grafts is not different in both groups at 18 weeks (Fig. 
17 2E). These results suggest that upregulation of insulin secreting capacity of the EPC grafts in the 
18 diabetic environment is not due to facilitated β-cell maturation from EPCs in grafts. Since host diabetic 
19 environment upregulates insulin secreting capacity of the grafts during the early post-implantation 
20 period (4 to 13 weeks) (Fig. 2B), we focused on early period for further analysis.
21 Next, to examine whether the positive effect of insulin-deficient diabetic condition on insulin 
22 secreting capacity of EPC grafts was iPSC line dependent, we used EPCs derived from another human 
23 iPSC cell line Ff-WJ18. Ff-WJ18 derived EPCs, which contained 97.8±1.0% of SOX17+ cells at 
24 definitive endoderm stage, 74.4±13.7% of PDX1+NKX6.1+ cells at pancreatic endoderm stage, and 
25 58.3±14.4% of CHGA+ cells and very few insulin-expressing cells at endocrine progenitor stage, were 
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1 implanted under the kidney capsule of STZ treated-diabetic NOD/SCID mice. During the period of 
2 hyperglycemia, plasma human C-peptide levels were sustainably increased up to 10 weeks post-
3 implantation in EPC-implanted mice while the increase were not evident in mice without STZ-
4 treatment (Fig. 3A and 3B). Additionally, we used Akita-NOD/SCID mice, which carry an Ins2Akita 
5 mutation resulting in insulin-dependent diabetes, to investigate the host-effect in another diabetic 
6 model. The levels of endogenous mouse insulin in plasma and pancreas were almost depleted in both 
7 diabetic models (Supplementary Fig. 5). Consistently, the intensity of hyperglycemia was similar 
8 between STZ-treated and Akita mice (Fig. 3C). By EPC implantation, plasma human C-peptide levels 
9 were sustainably increased up to 8 weeks post-implantation in all groups, while the levels were higher 
10 in diabetic mice than in corresponding non-diabetic control mice at each time point (Fig. 3D). These 
11 results suggest that the host-effect is cell-line independent and diabetic model independent.
12
13 Plasma insulin level is inversely associated with EPC graft insulin secreting capacity.
14 To determine the causative regulator of the host-effect, we investigated whether insulin deficiency 
15 in diabetes upregulates insulin secreting capacity of the grafts. Firstly, we subcutaneously implanted 
16 an osmotic pump to infuse human insulin at 40-60 nmol/kg/day before EPC implantation (Fig. 4A). 
17 The insulin infusion ameliorated STZ-induced hyperglycemia below average 300 mg/dl before and up 
18 to 11 weeks after EPC implantation. Plasma human insulin levels were increased by the insulin 
19 infusion while plasma human C-peptide levels were lowered to the levels in non-diabetic mice (Fig. 
20 4B and 4C).
21 Next, we used hyperinsulinemia model that is compensatory increase in endogenous insulin 
22 induced by feeding of a HFD. NOD/SCID mice were implanted EPCs and thereafter fed with CD or 
23 HFD for 12 weeks. Non-fasting blood glucose level was similar in mice fed with CD and HFD 12 
24 weeks post-implantation, except the HFD feeding induced hyperinsulinemia (Fig. 4D and 4E). In 
25 contrast to plasma insulin, plasma human C-peptide was downregulated up to 12 weeks post-
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1 implantation in HFD-fed mice (Fig. 4F). Based on the downregulation, the hyperinsulinemia in HFD-
2 fed mice was confirmed to be due to insulin resistance and compensatory upregulation of endogenous 
3 insulin secretion (Fig. 4E). Collectively, increase in plasma insulin attenuated human C-peptide 
4 secretion from the EPC grafts suggesting that insulin deficiency in the host plays a positive role in 
5 upregulation of insulin secreting capacity of the grafts.
6 To investigate the involvement of plasma glucose levels for the host-effect, hyperglycemia was 
7 attenuated without insulin supplementation in STZ-induced diabetic NOD/SCID mice before and after 
8 EPC implantation. Dapagliflozin, a selective SGLT2 inhibitor which inhibits renal glucose re-
9 absorption, was administered orally once daily at dose of 10 mg/kg, the dose estimated to lower blood 
10 glucose levels (26). The dapagliflozin treatment stably improved hyperglycemia yet the non-fasting 
11 blood glucose levels were over approximately 300 mg/dl even with EPCs implantation (Fig. 5A). After 
12 the EPC implantation, plasma human C-peptide levels in mice with dapagliflozin were comparable to 
13 that in mice with vehicle treatment (Fig. 5B) which were higher than that in non-diabetic mice. These 
14 results suggest that partial attenuation of hyperglycemia via insulin independent mechanism has little 
15 influence on the host-effect for EPC grafts.
16
17 Host diabetic environment affects EPC graft to increase endocrine cells including insulin producing 
18 cells without affecting graft mass.
19 To clarify how insulin secreting capacity is improved in the grafts, we analyzed cell mass and 
20 composition of the explanted EPC grafts at 6 weeks post-implantation. Appearance and weight of 
21 whole graft were not different between diabetic and non-diabetic mice despite different plasma human 
22 C-peptide levels at 6 weeks post-implantation (Fig. 6A and 6B, and Supplementary Fig. 6A). In 
23 contrast, whole graft contents of both insulin and glucagon were higher in the grafts from diabetic mice 
24 compared to that from non-diabetic mice (Fig. 6C). When analyzed individually, a strong positive 
25 correlation was shown between plasma human C-peptide levels on 6 weeks and insulin content of the 
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1 explanted grafts (Fig. 6D). In addition, grafts from diabetic mice contained approximately 3 times 
2 more immunoreactivity areas of CHGA and insulin while that of NKX6.1 and glucagon did not show 
3 significant differences (Fig. 6E-H). Moreover, insulin-immunoreactivity area in grafts from diabetic 
4 mice contained more INS+Ki67+ proliferative cells (Fig. 6I and Supplementary Fig. 6B). The grafts 
5 from both diabetic and non-diabetic mice contained PDX1+CK19+ duct-like structures in which SOX9+ 
6 progenitor cells were almost exclusively observed (Supplementary Fig. 6C). These structures included 
7 few CHGA+ cells, and similarly contained Ki67+ cells between grafts from diabetic and non-diabetic 
8 mice, suggesting that these are less likely to be related to the insulin secreting capacity of grafts. 
9 Regarding -cell maturation markers, immunofluorescence signals of urocortin-3 and MAFA in INS+ 
10 cells were not observed in either group (data not shown). Taken together, these results suggest that 
11 insulin-deficient diabetic condition in host increases endocrine cells including insulin producing cells 
12 without affecting graft mass at least via proliferation. We preliminary analyzed the grafts at 24 weeks 
13 post-implantation in another implantation study (Fig. 2), and found that the grafts from diabetic mice 
14 contained more insulin and glucagon compared to that from non-diabetic mice without affecting graft 
15 mass (Insulin: 5.27± 1.66 and 1.43± 0.52 nmol/whole graft in diabetic and non-diabetic mice, 
16 respectively; Glucagon: 1.59±0.27 and 0.37±0.02 nmol/whole graft in diabetic and non-diabetic 
17 mice, respectively). This suggests that the increase of insulin producing cells in diabetic hosts is 
18 maintained after reaching a plateau level in plasma hC-peptide.
19
20 Lowering insulin action directly promotes the differentiation of EPCs into INS+NKX6.1+ cells in 
21 vitro.
22 To examine the influence of glucose and insulin on the differentiation propensity of EPCs toward 
23 insulin-producing cells, EPCs were cultured for 10 days with previous report-based differentiation 
24 medium (18, 20). Under the condition of both low and high glucose, the differentiation induction 
25 efficiencies of INS+NKX6.1+ cells were slightly but significantly increased by adding an insulin 
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1 receptor antagonist S961 (Supplementary Fig. 7A and 7B). In addition, the proportion of 
2 INS+NKX6.1+ cells was also increased by changing the medium to be insulin free in the low glucose 
3 medium. The increase by changing to the insulin-free medium was not reached to statistical difference 
4 in the high glucose medium (p= 0.059). Regarding the influence of glucose, condition of high glucose 
5 did not increase the values of INS+NKX6.1+ cell proportion compared to that of low glucose. The 
6 proportion of INS+Ki67+ cells and the aggregate cell number did not differ between groups 
7 (Supplementary Fig. 7C-E). These results suggest that, at least in vitro differentiation induction system, 
8 lowering insulin action directly promotes the differentiation of EPCs into INS+NKX6.1+ cells.
9
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1 Discussion
2 Intensified research efforts are ongoing to establish cell therapy using stem cell-derived 
3 pancreatic cells against T1DM (4). One of the unsolved issues for their clinical application is an 
4 influence of the host environment on the cell fate after implantation. We examined whether host 
5 insulin-deficient diabetic condition affects the fate of hiPSC-derived EPCs in immunodeficient mice 
6 and made two major findings. Firstly, the host diabetic environment accelerates an increase in insulin 
7 secretion capacity of the EPC graft via mechanisms that involve insulin deficiency at least as a part. 
8 Secondary, the grafts from diabetic hosts contained more endocrine cells including insulin-producing 
9 cells without increasing graft mass compared to that from non-diabetic hosts. Based on highly positive 
10 correlation between insulin secretion capacity and insulin content of the EPC grafts, these two findings 
11 are likely to be related. 
12
13 The mechanism underlying accelerated increase in plasma human insulin/C-peptide levels in 
14 diabetic conditions (Figs. 2B, 3B, 3D, 4C, 5B, and 6A) could be explained by two intragraft events. 
15 One is increase in the number of INS+ cells in the grafts. The other potential explanation is increase in 
16 insulin secretory capacity from individual cells, which indicates accelerated maturation towards adult-
17 type β-cells. Immunohistochemical analyses suggest the former model by showing that EPC grafts 
18 contained more INS+ cells and proliferating INS+ cells in diabetic hosts (Fig. 6G-I). Additionally, 
19 despite findings in the in vitro model, lowering insulin action promoted the differentiation of EPCs 
20 into INS+NKX6.1+ cells without increasing the proportion of INS+Ki67+ cells (Supplementary Fig. 
21 7A-D), suggesting the shifted differentiation propensity toward INS+ cells is also possibly involved in 
22 the increased number of INS+ cells in diabetic hosts. On the other hand, plasma hC-peptide derived 
23 from EPC grafts responded to fed/fast status in both diabetic and non-diabetic mice even when the 
24 absolute values were different between the two groups (Fig. 2C). Considering the increase in INS+ cell 
25 number, there is no clear evidence to support the latter model. Therefore, we reason that the increased 
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1 number of INS+ cells mainly contributes to the accelerated increase in insulin secretion, at least in part 
2 via promoted proliferation of INS+ cells and possibly via the shifted differentiation propensity toward 
3 INS+ cells. 
4
5 The numerous alterations occur in diabetic condition such as abnormal insulin levels, 
6 hyperglycemia, and the resulting complications (2). Based on our findings from intervention of blood 
7 insulin levels (Fig. 4B and 4E) and in vitro experiments (Supplementary Fig. 7), we are proposing that 
8 insulin deficiency in host plays a positive role in upregulation of insulin secreting capacity of the EPC 
9 grafts. While there are no reports using human fetal pancreas to investigate the host effect post-
10 implantation as in this study, reports using hESC-derived PECs support this idea. During the early 
11 period after PECs implantation, diabetic mice showed higher plasma hC-peptide levels compared with 
12 non-diabetic mice and the increase was of lesser degree upon exogenous insulin supplementation (14). 
13 EPCs we used in this study are developmentally considered to contain less progenitors which possess 
14 potential to differentiate into non-endocrine cells compared to PECs. The observation of implanted 
15 PECs reported previously (14) might involve not only the differentiation propensity of non-endocrine 
16 progenitors but also proliferation of hormone-expressing cells in the grafts. Collectively, immature 
17 cell types such as PEC, EPC, and immature hormone-positive cells are likely to compensate a decrease 
18 in blood insulin levels. On the other hand, the involvement of blood glucose levels is not evident. In 
19 our study, the upregulation of insulin secreting capacity of EPC grafts was not affected when non-
20 fasting blood glucose levels were stably lowered by repeated dosing of dapagliflozin (Fig. 5B). Given 
21 dapagliflozin-treated mice still maintained around 300 mg/dl of non-fasting blood glucose levels even 
22 with EPC implantation, question of whether blood glucose levels less than 300 mg/dl could have direct 
23 effect on EPC graft remains to be solved.
24
25 Our finding from in vitro experiments that lowering insulin action facilitated the differentiation 
26 of EPCs into INS+ cells suggests the involvement of insulins signaling as a molecular mechanism 
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1 (Supplementary Fig. 7). Indeed, some reports have indicated the relevance of insulin signaling 
2 molecules to differentiation of immature pancreatic cells. Phosphatidylinositol 3-kinase (PI3K) is 
3 known to be activated by insulin, and its inhibition by wortmannin or Ly294002 facilitated 
4 differentiation of human fetal-derived islet-like cell clusters in vitro (27). Considering that PI3K 
5 functions as a negative regulator of islet development, this could be a mediator of our in vitro finding 
6 (Supplementary Fig. 7A and 7B). One of downstream molecules of PI3K is FOXO1 of which 
7 transcriptional activity is inhibited by activation of insulin signaling via phosphorylation at Ser256. 
8 Unlike PI3K inhibition, treatment with AS1842856, a chemical FOXO1 inhibitor, promoted 
9 differentiation from pancreatic progenitors to INS+ cells in hESCs (28). As FOXO1 was inhibited from 
10 pancreatic progenitor to INS+ cell differentiation in the report, the insulin action via FOXO1 inhibition 
11 seems to facilitate INS+ cell differentiation. Thus FOXO1 is less likely to be involved in a mechanism 
12 of our in vitro finding. Therefore, although the detail remains unknown, our proposed mechanism is 
13 that activation of insulin-signaling via PI3K through other downstream molecules than FOXO1 
14 negatively regulate differentiation into INS+ cells, while the attenuation of the signaling such as insulin 
15 deficient diabetic conditions results in facilitated differentiation. Regarding increase in proliferating 
16 INS+ cells found in vivo (Fig. 6I), we assume that some cell types other than implanted EPCs is 
17 involved, since increase in INS+Ki67+ cells was not observed in vitro (Supplementary Fig. 7C and 7D). 
18 Further studies with genetically modified mice in terms of insulin signaling may contribute to elucidate 
19 the direct target cells of insulin action in vivo.
20
21 We found that HFD feeding after implantation attenuates the insulin secreting capacity of the 
22 implanted cells (Fig. 4D-F), which is apparently conflicted with the previous report by Bruin et al. 
23 showing no impact on the implanted cells (29). However, the timing of HFD feeding is different 
24 between the two studies as we started immediately after implantation while cells were implanted 
25 following 7-week HFD feeding at which time the onset of insulin resistance was confirmed in the 
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1 report. We speculate the timing of onset of insulin resistance explains the major difference between 
2 the report and our findings since onset of insulin resistance may alter the whole body signaling state 
3 (30). In addition, the detailed experimental designs were different such as implantation site 
4 (subcutaneous space and kidney sub-capsule), encapsulation (an immunoisolative device and naked) 
5 and even cell type (PECs and EPCs). It is of interest to elucidate the mechanism underling the different 
6 behavior of immature pancreatic cells in the future studies.
7
8 In non-diabetic mice, plasma mouse insulin/C-peptide was decreased following EPC implantation 
9 (Supplementary Fig. 4). The similar phenomenon was observed in previous reports using PECs (31) 
10 and human islets (32). Mouse normoglycemia is considered mild hyperglycemic state for human islets, 
11 and xeno-islet grafts are reported to shift the glycemic levels to typical of the islet donor species in 
12 mice (32). Therefore, the lower threshold of glucose-stimulated insulin secretion from EPC grafts 
13 compared to endogenous islets is considered to cause the replacement of plasma mouse insulin with 
14 human insulin derived from EPC grafts in non-diabetic mice.
15
16 Post-transplant care for the recipients potentiates islet graft function (2). For example, the type of 
17 immunosuppressants affect the islet graft function in clinical setting (33). Another case is that 
18 reduction of adult islet graft workload by combination of fasting and insulin treatment during early 
19 post-transplant period improve the long-term engraftment in rats (34). In the current study, we 
20 demonstrated that exogenous insulin treatment to control blood glucose levels lowered the insulin 
21 secreting capacity of EPC grafts (Fig. 4C) which contained few insulin-expressing cells as of 
22 implantation (Fig. 1B and 1C, and Supplementary Fig. 1). Therefore, we speculate that insulin 
23 treatment as a post-transplant care might lower the therapeutic potential of the grafts for cell therapy 
24 against T1DM when using incompletely matured pancreatic endocrine cells. Recently, as a non-insulin 
25 adjunct pharmacological therapy against T1DM, SGLT2 inhibitors including dapagliflozin are 
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1 approved and reported to improve glycemic control with reducing total daily insulin doses (35). Since 
2 insulin deficiency is considered to potentiate function of the immature grafts, selection or 
3 combinational use of hypoglycemic agents other than insulin might be a good option to achieve post-
4 implantation glycemic control during graft maturation. Taken together, results in this study would 
5 contribute to gain insights for future cell therapy using alternative source of adult islets in terms of 
6 what therapy would serve as the most suitable post-implantation care for T1DM patients.
7
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12
13 Figure Legends 
14 Figure 1. In vitro generated EPC aggregates for implantation contain high proportion of 
15 CHGA+NKX6.1+ cells while very few INS+ or GCG+ cells. EPCs for implantation were generated 
16 from hiPSCs by stepwise differentiation. (A) A schematic diagram of the differentiation procedures. 
17 Representative cryosectional images of Ff-I14s04-derived EPC aggregates stained for (B) 
18 endocrine/endocrine progenitor marker CHGA and pancreatic progenitor marker NKX6.1 and (C) 
19 pancreatic hormones INS and GCG. Nuclei were stained with DAPI. The lower panels show magnified 
20 images. (D) Representative dot plots indicating differentiation efficiency into endocrine progenitor 
21 stage (CHGA+NKX6.1+ and CHGA+INS-). The differentiation induction efficiency was inserted. (E) 
22 A representative image of a host kidney with sub-capsular implantation of EPC aggregates. Scale bars, 
23 100 μm. See also Supplementary Figures 1-3.
24
25 Figure 2. Insulin-deficient diabetic environment in host upregulates insulin secreting capacity of 
26 the grafts derived from EPCs. NOD/SCID mice were injected intraperitoneally with 50 mg/kg of 
27 STZ for 5 consecutive days to induce diabetes or with vehicle buffer for non-diabetic control (nonSTZ). 
28 Six weeks later, each mouse was implanted Ff-I14s04-derived EPCs under the kidney sub-capsule 
29 (STZ-EPC and nonSTZ-EPC). Sham-operated STZ mice (STZ-sham) and non-operated nonSTZ mice 
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1 (nonSTZ-control) were also prepared. Levels of (A) non-fasting blood glucose and (B) plasma human 
2 C-peptide were measured at the indicated weeks after implantation in the indicated groups. (C) Plasma 
3 human C-peptide levels before and after an overnight fast were measured and (D) changes in the levels 
4 (D) were calculated at 13 and 18 weeks after implantation in the indicated groups. (E) An oral glucose 
5 tolerance test (2 g/kg) was performed at 18 weeks after implantation. Data are presented as the mean 
6 ± SD. *p < 0.05, **p < 0.01; STZ-EPC vs. nonSTZ-EPC by Bonferroni adjusted Student's or Aspin-
7 Welch's t-test in (B). *p < 0.05, **p < 0.01; fed vs. fasted by Student's or Aspin-Welch's paired t-test 
8 in (C and D). nonSTZ-control (N=3), nonSTZ-EPC (N=3-6), STZ-sham (N=4), and STZ-EPC (N =3-
9 6). See also Supplementary Figure 4.
10
11 Figure 3. The upregulated insulin secreting capacity of grafts in diabetic environment is 
12 reproduced when EPCs are derived from another hiPSC line or are implanted in genetically 
13 induced Akita model. (A and B) EPCs derived from Ff-WJ18 hiPSCs were implanted under the 
14 kidney capsule in STZ-induced diabetic and non-diabetic NOD/SCID mice (STZ-EPC and nonSTZ-
15 EPC, respectively). (C and D) EPCs derived from Ff-I14s04 hiPSCs were implanted not only in STZ-
16 induced diabetic NOD/SCID mice (STZ-EPC) but also in genetically induced Akita diabetic 
17 NOD/SCID mice (Akita-EPC). Each non-diabetic control mouse was implanted the EPCs similarly 
18 (nonSTZ-EPC and WT-EPC, respectively). In all experiments, levels of (A and C) non-fasting blood 
19 glucose and (B and D) plasma human C-peptide were measured at the indicated weeks after 
20 implantation. Data are presented as the mean ± SD. **p < 0.01 STZ-EPC vs. nonSTZ-EPC by ANOVA 
21 in (A) and (B). **p < 0.01 STZ-EPC vs. nonSTZ-EPC or Akita-EPC vs. WT-EPC by ANOVA in (C) 
22 and (D). nonSTZ-EPC (N=3-4) and STZ-EPC (N=5-6) in (A and B). nonSTZ-EPC (N=4), STZ-EPC 
23 (N=5-6), WT-EPC (N=3) and Akita-EPC (N=3-5) in (C and D). See also Supplementary Figure 5.
24
25 Figure 4. Both exogenous insulin supplementation and hyperinsulinemia induced by a HFD 
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1 feeding suppress the insulin secreting capacity of EPC-grafts. (A-C) Human insulin (40-60 
2 nmol/kg/day) was subcutaneously administered via osmotic pump before and after EPC implantation 
3 in STZ-induced NOD/SCID mice (STZ-insulin-EPC). STZ-induced NOD/SCID mice without insulin 
4 supplementation and non-diabetic control mice were implanted EPCs similarly (STZ-EPC and 
5 nonSTZ-EPC, respectively). Plasma levels of (A) blood glucose, (B) human insulin, and (C) human 
6 C-peptide at non-fasting state were measured at the indicated weeks after implantation. (C-E) Feeding 
7 of a HFD (60% kcal fat) was started in NOD/SCID mice at the same time as EPC implantation (HFD-
8 EPC). NOD/SCID mice fed control diet were implanted EPCs similarly (CD-EPC). Levels of (C) 
9 blood glucose and plasma levels of (D) mouse insulin and (E) human C-peptide at non-fasting state 
10 were measured at the indicated weeks after implantation. Data are presented as the mean ± SD. **p < 
11 0.01 STZ-EPC vs. STZ-insulin-EPC by ANOVA in (A-C). **p < 0.01 HFD-EPC vs. CD-EPC by 
12 Aspin-Welch's t-test in (D). **p < 0.01 HFD-EPC vs. CD-EPC by ANOVA in (E). nonSTZ-EPC 
13 (N=3), STZ-EPC (N=4) and STZ-insulin-EPC (N=7). CD-EPC (N=3) and HFD-EPC (N=4).
14
15 Figure 5. Partial attenuation of hyperglycemia by dapagliflozin has no effect on the insulin 
16 secreting capacity of EPC-grafts. The SGLT2 inhibitor dapagliflozin was repeatedly administered 
17 before and after EPC implantation in STZ-induced NOD/SCID mice (STZ-dapa-EPC). STZ-induced 
18 diabetic and non-diabetic NOD/SCID mice with vehicle treatment were implanted EPCs similarly 
19 (STZ-veh-EPC and nonSTZ-veh-EPC, respectively). Sham-operated STZ-diabetic mice with or 
20 without treatment of Dapagliflozin were also prepared (STZ-veh-sham and STZ-dapa-sham, 
21 respectively). Levels of (A) blood glucose and (B) plasma human C-peptide at non-fasting state were 
22 measured at the indicated weeks after implantation. Data are presented as the mean ± SD. **p < 0.01 
23 STZ-veh-EPC vs. STZ-dapa-EPC by ANOVA in (A). *p < 0.05, **p < 0.01 vs. nonSTZ-veh-EPC by 
24 Bonferroni adjusted Dunnett's test in (B). nonSTZ-veh-EPC (N=5), STZ-veh-sham (N=5), STZ-veh-
25 EPC (N=5), STZ-dapa-sham (N=6) and STZ-dapa-EPC (N=6).
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12 Figure 6. Diabetic environment in host affects EPC-grafts to increase endocrine cells including 
3 insulin producing cells without affecting graft mass. A cohort of STZ-induced diabetic and non-
4 diabetic NOD/SCID mice were implanted EPCs from the same batch, and the grafts were explanted 6 
5 weeks after the implantation (STZ-EPC and nonSTZ-EPC, respectively). (A) Plasma levels of human 
6 C-peptide were measured at the indicated weeks after implantation. (B) Weight of explanted whole 
7 grafts and (C) the contents of insulin and glucagon were measured. (D) Correlation between individual 
8 plasma human C-peptide level and graft insulin content and the correlation coefficient were shown. 
9 Representative immunofluorescence images of the grafts stained for (E) endocrine/endocrine 
10 progenitor marker CHGA and pancreatic progenitor marker NKX6.1 and (G) pancreatic hormones 
11 INS and GCG. In left panels, graft and kidney tissue are delineated by a dashed white line (scale bars, 
12 500 m). In right panels, higher magnifications are inset (scale bars, 50 m). Areas of (F) CHGA or 
13 NKX6.1 and (H) INS or GCG immunoreactivity relative to the total graft area for each graft. (I) 
14 Number of INS+Ki67+ cells relative to the total area of INS immunoreactivity for each graft. Data are 
15 presented as the mean ± SD. **p < 0.01 STZ-EPC vs. nonSTZ-EPC by ANOVA in (A). *p < 0.05 
16 nonSTZ-EPC vs. STZ-EPC by Aspin-Welch's or Student's t-test in (C, F, H, and I). N number of STZ-
17 EPC is 8 in (A), 5 in (B-D) and 3 in (F, H and I) and that of nonSTZ-EPC is 6 in (A), 3 in (B-D) and 
18 3 in (F, H and I). Nuclei were stained with DAPI. See also Supplementary Figure 6.
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 In vitro generated EPC aggregates for implantation contain high proportion of CHGA+NKX6.1+ cells while 
very few INS+ or GCG+ cells. 
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 Insulin-deficient diabetic environment in host upregulates insulin secreting capacity of the grafts derived 
from EPCs. 
190x254mm (300 x 300 DPI) 
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 The upregulated insulin secreting capacity of grafts in diabetic environment is reproduced when EPCs are 
derived from another hiPSC line or are implanted in genetically induced Akita model. 
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 Both exogenous insulin supplementation and hyperinsulinemia induced by a HFD feeding suppress the 
insulin secreting capacity of EPC-grafts. 
190x254mm (300 x 300 DPI) 
Page 33 of 46
For Peer Review Only
Diabetes
 Partial attenuation of hyperglycemia by dapagliflozin has no effect on the insulin secreting capacity of EPC-
grafts. 
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 Diabetic environment in host affects EPC-grafts to increase endocrine cells including insulin producing cells 
without affecting graft mass. 
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Online Supplemental Materials
In vitro differentiation of EPCs into insulin-producing cells
The EPC aggregates, generated by aggregation culture on a low-binding 96-well plate at a 
density of 30 × 103 cells/well, were cultured for 10 days in iMEM-B27 with 10 μM ALK5 Inhibitor 
II (SC-221234A; Santa Cruz Biotechnology), 100 nM LDN193189 hydrochloride (HY-12071A; 
Medchemexpress) and 1 μM L-3,3ʹ,5-triiodothyronine (64245; Merck Millipore). The medium 
contained 200 mg/dL glucose (low glucose) or was added glucose (G8769; Sigma) to set the 
concentration at 540 mg/dL (high glucose). To lower influence of insulin, B27 without containing 
insulin (A1895602; Thermo Fisher Scientific) instead of B27, or 100 nM of the synthetic peptide 
S961 (Phoenix Pharmaceuticals, Burlingame, CA, USA) was added in the medium. S961 at 100 nM 
was reported to function as a strong insulin receptor antagonist (1). Forty-eight aggregates were 
prepared for each group and the medium renewal was conducted once every 3 or 4 days. After 10 
days culture, the propensity to differentiate into INS+NKX6.1+ cells and INS+Ki67+ cells were 
assessed by flow cytometry (FCM). Three independent experiments using different batches of EPCs 
were conducted. The gate of FCM data analyzed for INS+NKX6.1+ cells was set to be under 1.5% at 
the starting point of 10-day culture in all experiments. The cell number was measured using NC200 
(Chemometec, Allerod, Denmark).
Reference
1. Knudsen L, Hansen BF, Jensen P, Pedersen TÅ, Vestergaard K, Schäffer L, Blagoev B, 
Oleksiewicz MB, Kiselyov VV, De Meyts P. Agonism and antagonism at the insulin receptor. 
PLoS One. 2012;7(12):e51972.
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Supplementary Table 1: Additional information on EPCs generated in vitro from hiPSCs.
In vitro differentiation
Figure iPSC line Period of stage 3 
(days)
Period of stage 5 
(days)
1, 6, S1, S2, S6, and 
S7
Ff-I14s14 2 3
2 and S4 Ff-I14s14 2 4
3A, 3B and 4A-C Ff-WJ18 2 3
3C, 3D, and S5 Ff-I14s14 3 3
4D-F Ff-WJ18 3 3
5 and S3 Ff-WJ18 2 3
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Supplementary Table 2: The information on antibodies used in this study.
Primary antibody Species Source Dilution
SOX2 Rabbit 35795, Cell Signaling Technology 1:100
SOX17 Goat AF1924, R&D Systems 1:500
FOXA2 Rabbit 07-633, EMD Millipore 1:100
PDX1 Goat AF2419, R&D Systems 1:200
NKX6.1 Mouse F55A12, University of Iowa 1:360
CHGA Rabbit ab68271, Abcam 1:500
Neurogenin3 Sheep AF3444, R&D Systems 1:2000
Insulin Rabbit C27C9, Cell Signaling Technology 1:200
*Insulin Rat GN-ID4, University of Iowa 1:600
Glucagon Mouse G2654, Sigma-Aldrich 1:200
Ki67 Mouse 550609, BD Pharmingen 1:100
Ki67 Rabbit D3B5, Cell Signaling Technology 1:100
CK19 Mouse M088, Dako 1:200
Trypsinogen Sheep AF3848, R&D Systems 1:100
SOX9 Rabbit ab196450, Abcam 1:100
Fluorescent secondary antibody Source Dilution
Nucleus Hoechst 33342; H3570, Invitrogen 1:200
Alexa 488 conjugated For each species; all from Invitrogen 1:500
*Alexa 546 conjugated For each species; all from Invitrogen 1:500
Alexa 594 conjugated For each species; all from Invitrogen 1:500
*: Used only for flow cytometry
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Supplementary Figures
Supplementary figure 1. EPCs are differentiated from hiPSCs by in vitro directed 
differentiation. Cell populations at individual stages were analyzed by flow cytometry. 
Representative dot plots indicating high differentiation efficiency of definitive endoderm 
SOX17+SOX2- cells at d3, posterior foregut PDX1+NKX6.1- cells at d9, pancreatic endoderm 
PDX1+NKX6.1+ cells at d14, and endocrine progenitor NKX6.1+CHGA+ and CHGA+INS- cells at 
d17. Each of these differentiation induction efficiencies is inserted.
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Supplementary figure 2. Immunostaining of the cell population in EPC aggregates. 
Representative immunofluorescence images of planar cultured cells stained for (A) SOX17/FOXA2 
and (B) PDX1/NKX6.1 at d3 and d14, respectively. (C) Representative cryosectional images of EPC 
aggregates stained for the indicated markers. Nuclei were stained with DAPI. Scale bars, 50 μm in 
(A) and (B); 100 μm in (C). TRP, trypsinogen. 
Page 40 of 46
For Peer Review Only
Diabetes
Supplementary figure 3. The proportion of NGN3+ cells is peak at the early phase of stage 5. 
Representative flow cytometry plots showing the proportion of NGN3+ cells at d14, d15 and d17 
during stage 5 differentiation in vitro.
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Supplementary figure 4. Endogenous insulin deficiency in diabetic mice is not affected by 
implantation of EPCs. STZ-induced diabetic NOD/SCID mice and non-diabetic control mice were 
implanted Ff-I04s04-derived EPCs under the kidney sub-capsule (STZ-EPC and nonSTZ-EPC). 
Sham-operated STZ mice (STZ-sham) were also prepared. Plasma levels of endogenous mouse 
C-peptide at non-fasting state were measured at the indicated weeks after implantation. Data are 
presented as the mean ± SD. **p < 0.01 nonSTZ-EPC vs. STZ-EPC by Bonferroni adjusted 
Dunnett's test. STZ-sham (N=4), STZ-EPC (N =3-6) and nonSTZ-EPC (N=3-6).
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Supplementary figure 5. Endogenous insulin is severely defected in diabetic mouse model used 
for implantation studies. Levels of (A) plasma mouse insulin levels at the day before 
EPC-implantation and (B) pancreatic insulin contents at 18 weeks after the EPC-implantation were 
measured in STZ-induced diabetic NOD/SCID mice and genetically induced Akita diabetic 
NOD/SCID mice. These levels in each non-diabetic control mice were measured similarly. Data are 
presented as the mean ± SD. *p < 0.05, **p < 0.01 STZ vs. nonSTZ or Akita vs. WT by 
Aspin-Welch's t-test. nonSTZ (N=4) and STZ (N=6) in (A). nonSTZ-EPC (N=4), STZ-EPC (N=5), 
WT-EPC (N=3) and Akita-EPC (N=3) in (B).
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Supplementary figure 6. Supplementary information referred to Figure 6. (A) Levels of blood 
glucose in STZ-induced diabetic and non-diabetic NOD/SCID mice before and after EPC 
implantation. Data are presented as the mean ± SD. STZ-EPC (N=8) and nonSTZ-EPC (N=6). 
Representative immunofluorescence images of the explanted grafts stained for (B) INS/Ki67 and (C) 
PDX1/CK19, PDX1/SOX9, CK19/CHGA and CK19/Ki67. Nuclei were stained with DAPI. Scale 
bars, 50 μm.
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Supplementary figure 7. Lowering insulin action directly promotes the differentiation of EPCs 
into INS+NKX6.1+ cells in vitro. The EPC aggregates were cultured for 10 days with previous 
report-based medium to induce the differentiation into insulin-producing cells. The medium 
contained glucose at 200 mg/dL (low) or 540 mg/dL (high). Under the both glucose concentration, 
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medium without containing insulin (insulin free) or added an insulin receptor antagonist S961 (100 
nM) was used. (A) Representative flow cytometry plots showing the proportion of INS+NKX6.1+ 
cells and (B) the average of three independent experiments. (C) Representative flow cytometry plots 
showing the proportion of INS+Ki67+ cells and (D) the average of three independent experiments. 
(E) Cell number of the aggregates after the 10-day culture. *p < 0.05, **p < 0.01 vs. control by 
Dunnett's test. 
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